Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age

Конечные точки клинических исследований в геронауке: показатели здоровья, биомаркеры и биологический возраст
Stephen B. Kritchevsky, Steven Ron Cummings
2022-10-19

aging-related conditionsbiological ageclinical outcomesgeroscience clinical trialssurrogate biomarkers
Treatments that target fundamental processes of aging are expected to delay several aging-related conditions simultaneously. Testing the efficacy of these treatments for potential anti-aging benefits will require clinical trials with endpoints that reflect the potential benefits of slowing processes of aging. There are several potential types of endpoints to capture the benefits of slowing a process of aging, and a consensus is needed to standardize and compare the results of these trials and to guide the analysis of observational data to support trial planning. Using biomarkers instead of clinical outcomes would substantially reduce the size and the duration of clinical trials. This requires validation of surrogate markers showing that treatment induced change in the marker reliably predicts the magnitude of change in the clinical outcome. The surrogate marker must also reflect the biological mechanism for the effect of treatment on the clinical outcome. "Biological age" is a superficially attractive marker for such trials. However, it is essential to establish that treatment induced change in biological age reliably predict the magnitude of benefits in the clinical outcome. Reaching consensus on clinical outcomes for geroscience trials and then validating potential surrogate biomarkers requires time, effort, and coordination that will be worthwhile to develop surrogate outcomes that can be trusted to efficiently test the value of many anti-aging treatments under development.
1
A valid surrogate marker must reflect the biological mechanism linking treatment to clinical outcomes, not merely correlate with them.
2
Biological age is an attractive potential marker, but its treatment-induced changes must be shown to reliably predict the magnitude of clinical benefits.
3
Biomarker endpoints could substantially reduce trial size and duration, but require validation that treatment-induced biomarker changes predict clinical outcome benefits.
4
Clinical outcomes should be standardized through consensus to enable comparison across geroscience trials and inform analysis of observational data for trial planning.
5
Geroscience treatments are expected to delay multiple aging-related conditions simultaneously, requiring endpoints that capture broad benefits of slowed aging processes.

endpoints for geroscience clinical trials, including health outcomes, biomarkers, and biological age

validation and standardization of clinical outcomes and surrogate biomarkers to assess whether anti-aging treatments slow aging processes and predict clinical benefits

Publication Details
Publication Date
2022-10-19
Journal
Publisher
ISSN
Cited by
58
Access Type
Author Information
Authors
Stephen B. Kritchevsky
Steven Ron Cummings
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%